20405 ⎘
Medicinal preparations containing organic active ingredients; Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom; Quinolines; Isoquinolines Morphinan derivatives, e.g. morphine, codeine
WOUND TREATMENTS AND COMPOSITIONS
#2COMPOSITIONS AND METHODS FOR TREATING STIMULANT-INDUCED AGITATION
#3COMPOUNDS AND COMBINATIONS THEREOF FOR TREATING NEUROLOGICAL AND PSYCHIATRIC CONDITIONS
#4COMPOUNDS AND COMBINATIONS THEREOF FOR TREATING NEUROLOGICAL AND PSYCHIATRIC CONDITIONS
#5METHODS AND PHARMACEUTICAL COMPOSITIONS TO TREAT DRUG OVERDOSE
#6MODIFYING EARLY-STAGE PARKINSON'S DISEASE PROGRESSION WITH DEEP BRAIN STIMULATION
#7COMPOUNDS AND COMBINATIONS THEREOF FOR TREATING NEUROLOGICAL AND PSYCHIATRIC CONDITIONS
#8BUPROPION DOSAGE FORMS WITH REDUCED FOOD AND ALCOHOL DOSING EFFECTS
#9TAMPER-RESISTANT PHARMACEUTICAL COMPOSITIONS OF OPIOIDS AND OTHER DRUGS
#10COMBINATION OF MITRAGYNINE AND NALTREXONE FOR SUBSTANCE USE DISORDERS
#11INTRANASAL PHARMACEUTICAL DOSAGE FORMS COMPRISING NALOXONE
#12COMPOSITIONS COMPRISING FLUMAZENIL AND NALTREXONE AND METHODS FOR USE THEREOF
#13COMPOUND SLOW-RELEASE IMPLANT OF NALTREXONE AND RISPERIDONE, PREPARATION METHOD THEREFOR, AND USE THEREOF
#14PHARMACEUTICAL FORMULATIONS COMPRISING NALTREXONE AND/OR BUPROPION
#15OPIOID FORMULATIONS
#16COMPOUNDS AND COMBINATIONS THEREOF FOR TREATING NEUROLOGICAL AND PSYCHIATRIC CONDITIONS
#17HIGH-DOSE NALOXONE FORMULATION
#18METHOD OF TREATING AMYOTROPHIC LATERAL SCLEROSIS WITH PRIDOPIDINE
#19METAP2 INHIBITORS AND METHODS OF TREATING OBESITY
#20TARGETED RELEASE RIFAXIMIN COMPOSITIONS
#21COMPOUNDS AND COMBINATIONS THEREOF FOR TREATING NEUROLOGICAL AND PSYCHIATRIC CONDITIONS
#22Encased Tamper Resistant Controlled Release Dosage Forms
#23KETAMINE OR DEXTROMETHORPHAN FORMULATIONS AND METHODS OF USE
#24COMPOUNDS AND COMBINATIONS THEREOF FOR TREATING NEUROLOGICAL AND PSYCHIATRIC CONDITIONS
#25PHARMACEUTICAL COMPOSITIONS COMPRISING BUPROPION AND CYSTEINE
#26PHARMACEUTICAL PREPARATION FOR INTRANASAL ADMINISTRATION AND PREPARATION METHOD THEREFOR
#27TECHNIQUES FOR PROVIDING INTERACTIVE CLINICAL DECISION SUPPORT FOR DRUG DOSAGE REDUCTION
#28COMPOSITIONS FOR DRUG ADMINISTRATION
#29MUCUS MEMBRANE FORMULATIONS AND USES THEREOF
#30PHARMACEUTICAL COMPOSITION FOR NASAL DELIVERY
#31BUPROPION AND DEXTROMETHORPHAN FOR REDUCTION OF SUICIDE RISK IN DEPRESSION PATIENTS
#32ACYLATED GLUCAGON ANALOGUES
#33METHODS OF ADMINISTERING NALBUPHINE
#34ESKETAMINE FOR USE IN TREATING MAJOR DEPRESSIVE DISORDER
#35Compositions and Methods for the Treatment of Opioid Overdose
#36DOSAGE FORMS AND METHODS FOR ENANTIOMERICALLY ENRICHED OR PURE BUPROPION
#37ANALYTE SENSOR
#38COMPOUNDS AND COMBINATIONS THEREOF FOR TREATING NEUROLOGICAL AND PSYCHIATRIC CONDITIONS
#39HIGHLY SOLUBLE FORMULATIONS OF HARMINE
#40Pharmaceutical Combinations for Treatment
#41PREPARATION METHOD OF LONG-ACTING SUSTAINED AND CONTROLLED RELEASE IMPLANT
#42METHODS AND COMPOSITIONS FOR WOUND HEALING
#43LYMPH DIRECTING PRODRUGS
#44STABLE PHARMACEUTICAL COMPOSITION OF BUPRENORPHINE AND PREPARATION METHOD AND USE THEREOF
#45ORGANIC COMPOUNDS
#46PREPARATION OF ABUSE-DETERRENT PHARMACEUTICAL FORMULATIONS USING VAPOR PHASE DEPOSITION
#47ANALGESIC DELTA OPIOID RECEPTOR BITOPIC LIGANDS
#48PHARMACEUTICAL RESINATE COMPOSITIONS AND METHODS OF MAKING AND USING THEREOF
#49METHODS FOR IMPROVING COGNITIVE FUNCTION
#50Tamper Resistant Pharmaceutical Formulations
#51IMMEDIATE RELEASE MULTILAYER TABLET
#52BUPROPION AS A MODULATOR OF DRUG ACTIVITY
#53COMPOSITIONS USING IRON EXCIPIENTS AND THEIR USES INCLUDING FOR THE TREATMENT OF CANCER
#54PHARMACEUTICAL RESINATE COMPOSITIONS AND METHODS OF MAKING AND USING THEREOF
#55TAMPER RESISTANT DOSAGE FORMS
#56Injector
#57COMBINATION FORMULATIONS OF NALOXONE AND ATIPAMEZOLE
#58BUPROPION AS A MODULATOR OF DRUG ACTIVITY
#59PHARMACEUTICAL COMPOSITIONS COMPRISING BUPROPION AND CYSTEINE
#60TREATMENT OF CHRONIC COUGH, BREATHLESSNESS AND DYSPNEA
#61PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING MENTAL DISORDER
#62TREATMENT OF POOR METABOLIZERS OF DEXTROMETHORPHAN WITH A COMBINATION OF BUPROPION AND DEXTROMETHORPHAN
#63ENZYME IMMOBILIZED ADHESIVE LAYER FOR ANALYTE SENSORS
#64LYMPH DIRECTING PRODRUGS
#65BUPROPION AS A MODULATOR OF DRUG ACTIVITY
#66Methods of Using Low Dose Naltrexone to Treat Chronic Pain
#67OPTIMIZED SIGMA-1 AGONIST METHOD OF RESPONDER SELECTION AND TREATMENT
#68BIODEGRADABLE COMPACTED FORMULATIONS AND METHODS OF USE AND MANUFACTURE THEREOF
#69TREATMENT AND MANAGEMENT OF AUGMENTATION IN RESTLESS LEGS SYNDROME
#70PHARMACEUTICAL FORMULATION
#71COMPOUNDS AND COMBINATIONS THEREOF FOR TREATING NEUROLOGICAL AND PSYCHIATRIC CONDITIONS
#72LYMPH DIRECTING PRODRUGS
#73SUBLINGUAL SUBSTANCE ABUSE DISORDER AND ANTI-ADDICTION LOZENGE
#74ESKETAMINE FOR USE IN TREATING MAJOR DEPRESSIVE DISORDER
#75PHARMACEUTICAL FORMULATIONS FOR ORAL ADMINISTRATION AND METHODS OF MAKING AND USING THE SAME
#76PHARMACEUTICAL COMPOSITIONS COMPRISING BUPROPION AND CYSTEINE
#77TOPICAL NALOXONE COMPOSITIONS AND METHODS FOR USING THE SAME
#78TREATMENT OF OPIOID USE DISORDER, OPIOID WITHDRAWAL SYMPTOMS AND CHRONIC PAIN
#79WEARABLE DEVICE FOR RECOGNITION AND RESPONSE TO AN OVERDOSE
#80METHODS AND COMPOSITIONS FOR PAIN MANAGEMENT
#81ABUSE AND MISUSE DETERRENT TRANSDERMAL SYSTEMS
#82NALTREXONE FOR BOOSTING THE THERAPEUTIC UTILTY OF 5-HT RECEPTOR AGONISTS
#83BUPROPION AS A MODULATOR OF DRUG ACTIVITY
#84LIPID DEPOT FORMULATIONS
#85EFFERVESCENT COMPOSITION AND METHOD FOR DETERMINING BITTERNESS PERCEPTION
#86NANOPARTICLE-BASED ABUSE-DETERRENT FORMULATIONS AND METHODS OF MAKING AND USING
#87Vaporized Medicants and Methods of Use
#88BUPROPION DOSAGE FORMS WITH REDUCED FOOD AND ALCOHOL DOSING EFFECTS
#89COMPOUNDS AND COMBINATIONS THEREOF FOR TREATING NEUROLOGICAL AND PSYCHIATRIC CONDITIONS
#90COMPOUNDS AND COMBINATIONS THEREOF FOR TREATING NEUROLOGICAL AND PSYCHIATRIC CONDITIONS
#91INTRANASAL EPINEPHRINE FORMULATIONS AND METHODS FOR THE TREATMENT OF DISEASE
#92IMMEDIATE RELEASE MULTILAYER TABLET
#93COMPOSITIONS, FORMULATIONS AND METHODS FOR STIMULATING RESPIRATION
#94BUPROPION DOSAGE FORMS WITH REDUCED FOOD AND ALCOHOL DOSING EFFECTS
#95COMPOUNDS AND COMBINATIONS THEREOF FOR TREATING NEUROLOGICAL AND PSYCHIATRIC CONDITIONS
#96TREATMENT OF POOR METABOLIZERS OF DEXTROMETHORPHAN WITH A COMBINATION OF BUPROPION AND DEXTROMETHORPHAN
#97ANTHOCYANIN -BASED COLORANT
#98COMPOSITIONS AND METHODS FOR IMMUNE-MEDIATED CANCER THERAPY
#99POLYSILANE METHACRYLIC COMPOUNDS AND METHODS OF MAKING THEM
#100PHARMACEUTICAL COMPOSITIONS COMPRISING BUPROPION AND CYSTEINE
#101COMPOUNDS AND COMBINATIONS THEREOF FOR TREATING NEUROLOGICAL AND PSYCHIATRIC CONDITIONS
#102COMPOUNDS AND COMBINATIONS THEREOF FOR TREATING NEUROLOGICAL AND PSYCHIATRIC CONDITIONS
#103METHODS OF TREATING DISEASE USING AURICULAR PERIPHERAL NERVE FIELD STIMULATION
#104NOVEL PHARMACEUTICAL FORMULATION
#105TAMPER RESISTANT DOSAGE FORMS
#106DISSOLVABLE-CHEWABLE TABLET
#107BLISTER PACK CONFIGURED TO HOLD AND/OR PREVENT INADVERTENT ACTUATION OF A DEVICE FOR ADMINISTERING A DRUG
#108MORPHINE FORMULATIONS
#109ALKALINE INTRAORAL PRODUCTS
#110SYNTHESIS OF MORPHINANS WITH REDUCED HERG ACTIVITY AND MOP BINDING
#111TOPICAL ADMINISTRATION TO THE ORAL CAVITY
#112PHARMACEUTICAL COMPOSITION FOR PREVENTING RELAPSE INTO CANNABIS USE AND APPLICATION THEREOF
#113DRUG DELIVERY DEVICE AND METHODS FOR USING SAME
#114PROCESS OF MAKING STABLE ABUSE-DETERRENT ORAL FORMULATIONS
#115BUPRENORPHINE DOSING REGIMENS
#116METHODS OF ADMINISTERING NALBUPHINE
#117PHARMACEUTICAL COMPOSITION FOR NASAL DELIVERY
#118BUPROPION AS A MODULATOR OF DRUG ACTIVITY
#119ANTIOBESITY COMPOSITIONS
#120METHODS AND COMPOSITIONS FOR PREVENTING AND TREATING FIBROSIS AND IMPROVING FUNCTIONAL RECOVERY AFTER INJURY OR WITH AGING
#121STABILIZED FORMULATIONS CONTAINING ANTI-INTERLEUKIN-6 RECEPTOR (IL-6R) ANTIBODIES
#122USE OF DEXTROMETHORPHAN IN COMBINATION WITH CYP2D6 AND CYP3A4 ENZYME INHIBITORS FOR THE TREATMENT OF PAIN
#123NALTREXAMINE DERIVATIVES BEARING 5-MEMBER HETEROCYCLIC RING SYSTEMS AND OPIOID RECEPTOR MODULATORS
#124COMPOUNDS AND COMBINATIONS THEREOF FOR TREATING NEUROLOGICAL AND PSYCHIATRIC CONDITIONS
#125COMBINATION NASAL AND ORAL THERAPY FOR WEIGHT LOSS
#126TREATMENT COMPOSITION FOR TREATING CHRONIC PAIN AND MIXED PAIN SITES
#127BUPROPION DOSAGE FORMS WITH REDUCED FOOD AND ALCOHOL DOSING EFFECTS
#128METHODS AND COMPOSITIONS FOR TREATING VASOMOTOR SYMPTOMS
#129METHODS OF TREATING CANCER AND OTHER CONDITIONS WITH A MU OPIOID RECEPTOR ANTAGONIST
#130USE OF AMISULPRIDE AS AN ANTI-EMETIC
#131BUPROPION DOSAGE FORMS WITH REDUCED FOOD AND ALCOHOL DOSING EFFECTS
#132TREATMENTS AND PREVENTION OF OPIOID NEONATAL ABSTINENCE SYNDROME
#133TREATMENT OF DEPRESSION
#134TARGETING PTCHD1 AND NEURONAL CHOLESTEROL TO ENHANCE SAFETY OF OPIOID ANALGESICS
#135POLYSUBUNIT OPIOID PRODRUGS RESISTANT TO OVERDOSE AND ABUSE
#136USE OF DEXTROMETHORPHAN IN COMBINATION WITH CYP2D6 AND CYP3A4 ENZYME INHIBITORS FOR THE TREATMENT OF PAIN
#137IMPLANTABLE DEVICES FOR THE SUSTAINED DELIVERY OF AN OPIOID ANTAGONIST AND METHODS FOR TREATING INFLAMMATORY, NEUROINFLAMMATORY AND METABOLIC DISORDERS
#138Compositions And Methods For Reducing Major Adverse Cardiovascular Events
#139Pharmaceutical Compositions
#140SLEEP DISORDER TREATMENT AND PREVENTION
#141NOVEL COMPOSITIONS
#142METHODS OF TREATING ACUTE DEPRESSION AND ANXIETY
#143ABUSE DETERRENT MORPHINE SULFATE DOSAGE FORMS
#144COMPOSITIONS AND METHODS FOR THE TREATMENT OF OPIOID OVERDOSE
#145OPIOID RECEPTOR MODULATORS
#146COMBINATION OF DEXTROMETHORPHAN AND BUPROPION FOR TREATING DEPRESSION
#147COMPOUNDS AND COMBINATIONS THEREOF FOR TREATING NEUROLOGICAL AND PSYCHIATRIC CONDITIONS
#148TOPICAL NALTREXONE AS A TREATMENT FOR DRY EYE
#149APPARATUS, METHODS, AND SYSTEMS FOR PROVIDING PHARMACEUTICAL COMPOSITIONS IN THE FORM OF DROPLETS FOR AEROSOL ADMINISTRATION AND INHALATION DELIVERY
#150Diagnostic Opioid Taper Regimen
#151WOUND TREATMENTS AND COMPOUNDS
#152BUPROPION AS A MODULATOR OF DRUG ACTIVITY
#153Base Composition for Tape Agent
#154SACCHARIDE-BASED ORAL MUCOADHESIVE DELIVERY SYSTEM FOR PHARMACEUTICAL COMPOSITIONS
#155SACCHARIDE-BASED ORAL MUCOADHESIVE DELIVERY SYSTEM FOR NUTRITIONAL AND NUTRACEUTICAL COMPOSITIONS
#156Tamper resistant dosage forms
#157USE OF OPIOID FOR TREATMENT OF AUTISM SPECTRUM DISORDERS
#158SMALL MOLECULE ADRENORECEPTOR ANTAGONISTS AND USES THEREOF
#159COMPOUNDS AND COMBINATIONS THEREOF FOR TREATING NEUROLOGICAL AND PSYCHIATRIC CONDITIONS
#160TAMPER RESISTANT DOSAGE FORMS
#161OPIOID RECEPTOR ANTAGONIST PRODRUGS
#162COMPOUNDS AND COMBINATIONS THEREOF FOR TREATING NEUROLOGICAL AND PSYCHIATRIC CONDITIONS
#163ABUSE-RESISTANT MUCOADHESIVE DEVICES FOR DELIVERY OF BUPRENORPHINE
#164DEVICES AND METHODS FOR DELIVERY OF PHARMACEUTICAL COMPOSITIONS
#165METHODS OF TREATING PROSTATE CANCER OR METASTASIZED PROSTATE CANCER
#166Opioid formulations
#167Injectable Medical Formulation for Spinal Anesthesia, Process of Preparing, and Process of Administering
#168PHARMACEUTICAL COMPOSITIONS COMPRISING BUPROPION AND CYSTEINE
#169LIPOSOME LOADING
#170INJECTABLE BUPRENORPHINE FORMULATION
#171PRIMING OF CANCER CELLS WITH LOW DOSE NALTREXONE
#172METHODS FOR TREATING PRURITUS
#173LEVORPHANOL PRODRUGS AND PROCESSES FOR MAKING AND USING THEM
#174BUPROPION AS A MODULATOR OF DRUG ACTIVITY
#175COMPOUNDS AND COMBINATIONS THEREOF FOR TREATING NEUROLOGICAL AND PSYCHIATRIC CONDITIONS
#176STABLE FORMULATIONS OF BUPRENORPHINE
#177PHARMACEUTICAL DOSAGE FORMS
#178COMPOUNDS AND COMBINATIONS THEREOF FOR TREATING NEUROLOGICAL AND PSYCHIATRIC CONDITIONS
#179METHODS OF DIAGNOSING AND TREATING OSTEOARTHRITIS
#180COMPOSITIONS AND METHODS FOR TREATING OPIOID DEPENDENCE AND WITHDRAWAL
#181RAPIDLY DISSOLVING SALT TABLET COMPOSITIONS AND METHODS
#182USE OF APOMORPHINE AS THERAPEUTIC AGENT FOR NECROPTOSIS-RELATED DISEASES
#183ORAL TABLET WITH IMPROVED UNIFORMITY OF CONTENT OF ACTIVES
#184TREATMENT OF CHRONIC COUGH, BREATHLESSNESS AND DYSPNEA
#185Tamper Resistant Immediate Release Formulations
#186METHODS AND COMPOSITIONS FOR THE TREATMENT OF DRUG OVERDOSE
#187Multi-Layered Dextrose Tablets
#188DOPAMINE D3 RECEPTOR SELECTIVE ANTAGONISTS/PARTIAL AGONISTS AND USES THEREOF
#189METHOD OF TREATMENT AND DOSAGE FORMS THEREOF
#190BUPROPION AS A MODULATOR OF DRUG ACTIVITY
#191TAMPER RESISTANT DOSAGE FORMS
#192COMPOSITIONS, DEVICES, AND METHODS FOR THE TREATMENT OF OVERDOSE AND REWARD-BASED DISORDERS
#193COMPOSITIONS, DEVICES AND METHODS FOR THE TREATMENT OF ALCOHOL USE DISORDER
#194Vaginal Drug Delivery Device
#195OPIOID OVERDOSE RESCUE DEVICE
#196ORAL SOFT CAPSULE THAT ENCAPSULATES A NALBUPHINE FORMULATION
#197POLYSUBUNIT OPIOID PRODRUGS RESISTANT TO OVERDOSE AND ABUSE
#198PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CANCERS
#199NEW ABUSE-RESISTANT PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF OPIOID DEPENDENCE
#200BUPROPION AND DEXTROMETHORPHAN FOR REDUCTION OF SUICIDE RISK IN DEPRESSION PATIENTS
#201VARIOUS COMPOUNDS FOR THE TREATMENT OF NEUROFIBROMATOSIS TYPE 1
#202USE OF MORPHINAN DERIVATIVES FOR TREATMENT OF OPIOID DELTA RECEPTOR AGONIST-RELATED DISEASE
#203Methods For Administering Weight Loss Medications
#204Liquid Resin Extended-Release Oral Naltrexone Formulation for Treating Autism-Related Disorders
#205BUPROPION AS A MODULATOR OF DRUG ACTIVITY
#206STABLE PHARMACEUTICAL COMPOSITION OF METHYLNALTREXONE FOR AN ORAL ADMINISTRATION
#207Systems and Methods for Treating an Opioid-Induced Adverse Pharmacodynamic Response
#208TREATMENT COMPOSITIONS AND METHODS
#209The Overdose Reviver Automatic Inhaler
#210PHENYLEPHRINE HYDROCHLORIDE-CONTAINING TABLET, PREPARATION METHOD AND USE
#211THERAPEUTIC SUSPENSION COMPOSITIONS
#212METHODS AND COMPOSITIONS FOR POTENTIATING THE ACTION OF OPIOID ANALGESICS USING IBOGA ALKALOIDS
#213COMPOSITIONS FOR OPIATE AND OPIOID PREVENTION AND REVERSAL, AND METHODS OF THEIR USE
#214LOW-DOSE NALTREXOL AND USES THEREOF
#215KETAMINE OR DEXTROMETHORPHAN FORMULATIONS AND METHODS OF USE
#216PYRAZINE-CONTAINING COMPOUND
#217SUBCUTANEOUS BIODEGRADABLE NALTREXONE IMPLANT AND ACCOMPANYING BEHAVIORAL PROGRAM FOR WEIGHT LOSS IN A PATIENT
#218METHODS FOR PREVENTING AND TREATING CHRONIC PAIN
#219COMPOUNDS AND COMBINATIONS THEREOF FOR TREATING NEUROLOGICAL AND PSYCHIATRIC CONDITIONS
#220TREATMENT OF POOR METABOLIZERS OF DEXTROMETHORPHAN WITH A COMBINATION OF BUPROPION AND DEXTROMETHORPHAN
#221Drug delivery device and methods for using same
#222READY-TO-ADMINISTER HYDROMORPHONE FORMULATIONS
#223NALTREXONE FOR IMPROVING THE EFFECTIVENESS OF 5-HT RECEPTOR SUBTYPE 2A, 2B or 2C AGONISTS
#224Methods for treating antipsychotic-induced weight gain
#225TREATMENT FOR AUTOIMMUNE DISEASES
#226COMPOSITIONS COMPRISING AN AGONIST OF 5-HYDROXYTRYPTAMINE (5-HT) RECEPTOR SUBTYPE 3
#227Pharmaceutical compositions comprising bupropion and cysteine
#228Methods and compositions for treating cancer
#229COMBINATION OF DEXTROMETHORPHAN AND BUPROPION FOR TREATING DEPRESSION
#230PHARMACEUTICAL DOSAGE FORMS
#231ABUSE-RESISTANT MUCOADHESIVE DEVICES FOR DELIVERY OF BUPRENORPHINE
#232ASSESSING AND TREATING OBESITY
#233METHODS OF TREATING TRAUMATIC BRAIN INJURY AND RELATED NEUROLOGICAL CONDITIONS
#234NOVEL METHODS
#235Pharmaceutical composition for nasal delivery
#236Methods and Compositions for Treating Vasomotor Symptoms
#237GASTRIC RESIDENCE SYSTEMS COMPRISING BUPRENORPHINE AND NALOXONE
#238BUPROPION AND DEXTROMETHORPHAN FOR TREATING NICOTINE ADDICTION
#239DEVICE, METHOD, AND SYSTEM FOR PELVIC FLOOR REHABILITATION
#240METHOD OF MAINTAINING REMISSION OF DEPRESSIVE SYMPTOMS
#241HYDROMORPHONE FORMULATIONS FOR MULTI-DOSE PRODUCTS
#242Encased Tamper Resistant Controlled Release Dosage Forms
#243DRUG PRODUCTS FOR INTRANASAL ADMINISTRATION AND USES THEREOF
#244Apparatus, methods, and systems for providing pharmaceutical compositions and administering medications to patients
#245OPIOID FORMULATIONS
#246Tamper resistant dosage forms
#247TRANSMUCOSAL DRUG DELIVERY DEVICES FOR USE IN CHRONIC PAIN RELIEF
#248DRUG PRODUCTS FOR INTRANASAL ADMINISTRATION AND USES THEREOF
#249TREATMENT OF NEUROLOGICAL DISORDERS
#250TRANSDERMAL DELIVERY OF DEXTROMETHORPHAN
#251MICROSPHERE FORMULATIONS COMPRISING NALMEFENE ANDMETHODS FOR MAKING AND USING THE SAME
#252BIVALENT LIGANDS TO UNDERSTAND DIMERIZATION OF THE MU OPIOID RECEPTOR AND THE CHEMOKINE RECEPTOR CCR5 IN NEUROLOGICAL DISORDERS
#253BIODEGRADABLE COMPACTED FORMULATIONS AND METHODS OF USE AND MANUFACTURE THEREOF
#254Bupropion dosage forms with reduced food and alcohol dosing effects
#255FORMULATIONS AND METHODS FOR THE PREVENTION OF OPIOID OVERDOSE
#256THERAPEUTIC OR PROPHYLACTIC AGENT FOR CACHEXIA ACCOMPANIED BY GHRELIN RESISTANCE
#257SUSTAINED-RELEASE INJECTABLE COMPOSITION CONTAINING NALTREXONE AND METHOD FOR PREPARING SAME
#258BUPROPION AND DEXTROMETHORPHAN FOR TREATING NICOTINE ADDICTION
#259BUPROPION AS A MODULATOR OF DRUG ACTIVITY
#260METHODS AND COMPOSITIONS FOR MAINTAINING OPIOID EFFICACY IN THE TREATMENT OF PAIN
#261DEXTROMETHORPHAN TRANSDERMAL DELIVERY DEVICE
#262EASY CHEW FORMULATIONS
#263IMPLANTABLE DEVICES FOR DRUG DELIVERY WITH REDUCED BURST RELEASE
#264METHOD FOR PREPARING MICROPARTICLES CONTAINING POORLY SOLUBLE DRUGS
#265USE OF KAPPA OPIOID RECEPTOR AGONISTS TO TREAT CARDIOVASCULAR DISEASE
#266ANTI-CGRP COMPOSITIONS AND USE THEREOF
#267TIANEPTINE OXALATE AND NALOXONE COMBINATION FOR THE TREATMENT OF MAJOR DEPRESSIVE DISORDER
#268POLYSUBUNIT OPIOID PRODRUGS RESISTANT TO OVERDOSE AND ABUSE
#269TOPICAL NALOXONE COMPOSITIONS AND METHODS FOR USING THE SAME
#270TREATMENT OF DEPRESSION
#271COMPOSITIONS AND METHODS FOR OPIOID ANTAGONIST DELIVERY
#272ABUSE-RESISTANT MUCOADHESIVE DEVICES FOR DELIVERY OF BUPRENORPHINE
#273HIGH CONCENTRATION SUSPENSION FORMULATION FOR COLD AND FLU SOFT GEL CAPSULE MEDICATIONS
#274Liquisoft capsules
#275ORALLY ADMINISTRABLE FORMULATION
#276TRANSMUCOSAL DELIVERY DEVICE WITH ENHANCED UPTAKE
#277Compounds and combinations thereof for treating neurological and psychiatric conditions
#278Bupropion dosage forms with reduced food and alcohol dosing effects
#279TRANSMUCOSAL DRUG DELIVERY DEVICES FOR USE IN CHRONIC PAIN RELIEF
#280ACYLATED GLUCAGON ANALOGUES
#281METHODS OF TREATING OR PREVENTING CACHEXIA
#282ANALYTE SENSOR
#283OPIOID OVERDOSE REVERSAL MIXTURES
#284OPIOID FORMULATIONS
#285MEDICAL IMPLANT
#286TRANSMUCOSAL DRUG DELIVERY DEVICES FOR USE IN CHRONIC PAIN RELIEF
#287PROCESS OF MAKING STABLE ABUSE-DETERRENT ORAL FORMULATIONS
#288KETAMINE OR DEXTROMETHORPHAN FORMULATIONS AND METHODS OF USE
#289Morphinan compounds
#290DIPHENHYDRAMINE AND LACTOFERRIN FOR PREVENTION AND TREATMENT OF COVID-19
#291COMPOUNDS AND COMBINATIONS THEREOF FOR TREATING NEUROLOGICAL AND PSYCHIATRIC CONDITIONS
#292Tamper resistant dosage forms
#293SACCHARIDE-BASED ORAL MUCOADHESIVE DELIVERY SYSTEM FOR NEUROTROPHIC AND NEUROPROTECTIVE COMPOSITIONS
#294ABUSE-RESISTANT MUCOADHESIVE DEVICES FOR DELIVERY OF BUPRENORPHINE
#295NALTREXONE COMPOSITIONS
#296COMPOSITIONS FOR ORAL MUCOADHESIVE DOSAGE FORMS
#297THERAPEUTIC FORMULATIONS AND USES THEREOF
#298MORPHINAN COMPOUNDS
#299IMMEDIATE RELEASE MULTILAYER TABLET
#300Nucleic acids encoding peptides that block binding of a2d-1 to glutamate receptors for treating diseases and disorders